ABOUT US
Protecting Life with First-in-class Vaccines
About Us
Hong Kong Universal Biologicals Company Limited (HKUBio) is a Hong Kong -based biotech R&D Company, spinoff from The University of Hong Kong (HKU), Centre for Virology, Vaccinology and Therapeutics (CVVT), and in collaboration with The State Key Laboratory for Emerging Infectious Diseases (SKLEID) of the Department of Microbiology at the University of Hong Kong. It is part of the Health@InnoHK initiatives, funded by the Innovation and Technology Commission (ITC). We set up at the Hong Kong Science Park in developing innovative vaccine products for respiratory infectious diseases.
.jpg)
Based in Hong Kong and Greater Bay regions, HKUBio is collaborating with partners in China and overseas with strategic technology platforms for the rapid response to future epidemics and pandemic respiratory infectious diseases.
HKUBio is currently focus on developing a nasal spray multivalent flu vaccine and a combo vaccine for flu and COVID-19. The Flu-based viral vector vaccine platform is one novel strategy with a multi-purpose for the development of an intranasal vaccine for influenza, COVID-19, and other future respiratory viral diseases.
Meet The Experts
World-leading R&D Team
10+
PhD Scientists
10+
Years of Experience
OUR VALUED PARTNERS & COOPERATORS
Joining Hands to Combat Respiratory Diseases
